Study: SPECT biomarker assessment could aid ovarian cancer treatment

09/18/2013 | MolecularImaging.net

A study in the Journal of Nuclear Medicine suggests that using SPECT to assess expression of vascular cell adhesion molecule-1 may help predict therapeutic response and possibly improve outcomes for patients with metastatic ovarian cancer. Among 32 patients assessed with SPECT imaging, researchers found that VCAM-1 expression was present in 15% of women after chemotherapy, compared with 72% of those who only received surgery. "[T]hese observations indicate that in addition to the presence of VCAM-1 at the earliest stages of peritoneal spread (i.e., stage II patients with secondary implants), expression is responsive to treatment," researchers wrote.

View Full Article in:

MolecularImaging.net

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL